Last updated: February 15, 2026
What Is the Current Market Status for NDC 69238-1205?
The drug identified as NDC 69238-1205 is Vyepti (eptinezumab-vfrm), developed by Lundbeck. It is a monoclonal antibody approved by the FDA in February 2020 for the preventive treatment of migraine in adults. It is administered via intravenous infusion quarterly.
Current market dynamics indicate that Vyepti is positioned as a competitor within the migraine prophylaxis space, primarily competing with drugs such as:
- Aimovig (erenumab)
- Emgality (galcanezumab)
- Ajovy (fremanezumab)
- Nurtec ODT (rimegepant)
As of 2023, the migraine preventive segment shows increasing adoption driven by unmet needs in patients with frequent episodic or chronic migraines.
How Has the Market for Migraine Preventive Treatments Evolved?
Market Size and Growth
- The global migraine drug market in 2022 was valued at approximately USD 4.8 billion.
- Forecasted CAGR (compound annual growth rate) from 2023 to 2028 is estimated at 6.2% (Source: Grand View Research).
- The segment for biologic and monoclonal antibody therapies is expanding rapidly, representing roughly 40% of the total market by 2025.
Key Drivers
- Increasing prevalence of migraines, estimated at 15-20% globally.
- Limitations and side effects associated with traditional therapies (serotonin receptor agonists, beta-blockers).
- Growing insurance reimbursement and healthcare access for biologic treatments.
- Patient preference for quarterly IV administration in contrast to more frequent injections.
Competitive Landscape
- Aimovig led the migraine biologic market as of 2022, with approximately USD 950 million in global sales.
- Emgality and Ajovy followed, with sales reaching USD 549 million and USD 440 million, respectively.
- Vyepti’s sales were approximately USD 296 million in 2022, indicating rapid growth but still trailing behind Aimovig.
Price Projections for NDC 69238-1205 (Vyepti)
Pricing Overview
- The wholesale acquisition cost (WAC) for Vyepti in the US is approximately USD 6,650 per infusion.
- Insurance reimbursements generally factor in negotiated discounts, significantly lowering the net price paid by payers and patients.
- The average annual treatment cost per patient ranges from USD 26,600 to USD 36,800, assuming quarterly infusions.
Market Penetration and Revenue Forecasts
- 2023: Estimated US sales of USD 350-400 million.
- 2024: Projected growth to USD 500-550 million, tied to increased adoption.
- 2025: Expected to approach USD 700 million, assuming continued market penetration and stable pricing structures.
Price Sensitivity and External Factors
- Payers could negotiate discounts or formulary placements, reducing net revenue.
- Entry of biosimilar competitors or new blockbuster biologics may exert downward pressure.
- Changes in healthcare policy affecting drug pricing and reimbursement could alter projections.
Market Access and Reimbursement
- Vyepti's approval status and insurance coverage influence actual market penetration.
- In the US, coverage is high due to FDA approval and inclusion in treatment guidelines.
- International markets exhibit variation; Western European countries show similar adoption levels, while emerging markets await broader access.
Key Factors Influencing Future Price and Market Size
- Release of long-term efficacy and safety data could influence physician prescribing behavior.
- FDA or global regulatory approvals for additional indications could expand market scope.
- Competitive dynamics and patent expirations in the biologic migraine space will impact pricing.
- Potential development of biosimilars or generic versions remains a longer-term risk.
Summary Table: Market Data and Projections
| Metric |
2022 |
2023 (Estimate) |
2024 (Forecast) |
2025 (Forecast) |
| Global migraine drug market (USD) |
4.8 billion |
N/A |
N/A |
N/A |
| Vyepti US sales (USD) |
~296 million |
350-400 million |
500-550 million |
~700 million |
| Number of annual infusions sold |
Estimated 1.2-1.4 million |
N/A |
N/A |
Increasing proportion of total sales |
| Average treatment cost (USD) |
26,600 – 36,800 |
Similar to 2022 |
Slight increase as market expands |
Market stabilization expected |
Key Takeaways
- The migraine prophylaxis market is rapidly expanding, driven by biologic therapies like Vyepti.
- Vyepti's US sales are projected to grow from USD 296 million in 2022 to roughly USD 700 million by 2025.
- Pricing is anchored around a USD 6,650 infusion cost, with significant discounts in practice.
- Market growth depends heavily on payer access, competition, and long-term efficacy data.
- Price pressures are likely as biosimilars and new treatments enter the market.
FAQs
1. What are the main competitive advantages of Vyepti?
Vyepti offers quarterly IV infusions, reducing patient administration frequency, which can improve adherence over weekly or monthly injections used by competitors.
2. How does Vyepti’s pricing compare to other biologics for migraine?
Vyepti’s infusion cost is similar to Aimovig’s injection-based therapies, but the quarterly infusion can reduce administration costs and influence treatment preferences.
3. What are the risks to revenue growth for Vyepti?
Patent expiration, biosimilar entry, reimbursement reductions, and competitive new therapies pose potential risks.
4. How does international regulation affect global sales?
Regulatory approval varies; Europe approved Vyepti in 2021. Access depends on local pricing policies, healthcare infrastructure, and market demand.
5. What future indications could expand the market for Vyepti?
Potential for additional indications such as cluster headaches or other migraine subtypes could broaden market reach, depending on future clinical trial outcomes.
References
- Grand View Research. Migraine Drugs Market Analysis, 2023-2028.
- Drugs.com. Vyepti (Eptinezumab) Prescribing Information, 2020.
- Lundbeck. Vyepti Product Information.
- IQVIA. Annual Market Reports, 2022-2023.
- U.S. Food & Drug Administration. Vyepti (Eptinezumab) approval, 2020.
